These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Green BD, Gault VA, O'Harte FP, Flatt PR. Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953 [Abstract] [Full Text] [Related]
12. Circulation and degradation of GIP and GLP-1. Deacon CF. Horm Metab Res; 2004 Dec 03; 36(11-12):761-5. PubMed ID: 15655705 [Abstract] [Full Text] [Related]
13. Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets. Cassidy RS, Irwin N, Flatt PR. Biol Chem; 2008 Feb 03; 389(2):189-93. PubMed ID: 18163884 [Abstract] [Full Text] [Related]
14. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16). Irwin N, Green BD, Parker JC, Gault VA, O'Harte FP, Flatt PR. Regul Pept; 2006 Jul 15; 135(1-2):45-53. PubMed ID: 16675042 [Abstract] [Full Text] [Related]
15. The bioactive conformation of glucose-dependent insulinotropic polypeptide by NMR and CD spectroscopy. Alaña I, Malthouse JP, O'Harte FP, Hewage CM. Proteins; 2007 Jul 01; 68(1):92-9. PubMed ID: 17393464 [Abstract] [Full Text] [Related]